Image

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
18 years of age
Both
Phase 2

Powered by AI

Overview

The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease.

BV is a type of drug called an antibody-drug conjugate (ADC). ADCs are a substance made up of a monoclonal antibody chemically linked to a drug. Antibodies are proteins made by the immune system to fight infections and other possible harms to the body. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer cells. The linked drug enters these cells and kills them without harming other cells. Researchers think BV may be an effective treatment for this type of cancer because the drug targets cells that have CD30, which play a role in cancer cell growth. By destroying these cells, BV may help slow or stop the growth of the cancer. AVD (doxorubicin, vinblastine, and dacarbazine) is a treatment regimen that works by stopping the growth of cancer cells, either by killing the cells or by stopping them from dividing. The researchers think that BV in combination with AVD may work better than AVD alone to slow or stop the growth of the cancer.

Eligibility

Inclusion Criteria:

  • Histological diagnosis of classical, CD30-positive Hodgkin lymphoma confirmed at enrolling institution.
  • Ann Arbor stage I or II FDG-avid disease by FDG-PET/CT.
  • Disease bulk defined as any lymph node mass with transverse maximal diameter ≥ 7.0 cm or coronal maximal diameter ≥ 7.0 cm on CT imaging.
  • Age 18 and over.
  • ECOG Performance Status ≤ 2
  • Females of childbearing age must be on an acceptable form of birth control per institutional standards during the treatment period.
  • Males must consistently use an acceptable form of contraception per institutional standards during the treatment period.

Exclusion Criteria:

  • Prior systemic therapy or radiation therapy for Hodgkin lymphoma (excluding corticosteroids)
  • Cardiac ejection fraction < 50% as measured by echocardiogram.
  • Platelet count ≤ 75,000/µL.
  • Hemoglobin level ≤ 7.0 mg/dL.
  • Absolute neutrophil count ≤ 1.0 K/µL.
  • Serum creatinine clearance < 30 mL/minute as estimated by the Cockcroft-Gault Method.
  • Transaminase levels > 3 times the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, > 5 times the upper limit of normal is exclusionary.
  • Total bilirubin ≥ 1.5 the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, > 3 times the upper limit of normal is exclusionary.
  • Pre-existing peripheral neuropathy ≥ grade 2 prior to participation.
  • Known pregnancy or breast-feeding
  • Active viral infection with hepatitis B or hepatitis C. For hepatitis B, patients who are seropositive (hepatitis B core Ab positive) are permitted if HBV DNA is negative by PCR. For hepatitis C, patients who are seropositive (hepatits C Ab positive) are eligible if HCV DNA is negative by PCR and curative therapy has been completed.
  • Concurrent malignancy requiring active therapy within the last 2 years with the exception of basal cell or squamous cell carcinoma limited to the skin, carcinoma in situ of the cervix, breast or localized prostate cancer. Adjuvant hormonal therapy for cancer previously treated for curative intent is permitted.
  • Patients with autoimmune conditions requiring active, ongoing systemic immunosuppressive therapy.
  • Medical illness unrelated to Hodgkin lymphoma which in the opinion of the treating physician and/or principal investigator makes participation inappropriate.
        Note: Patients with HIV infection are permitted to enroll but are required to be on
        antiretroviral regimens that are in accordance with the current International AIDS Society
        guidelines concurrently with chemotherapy. Use of experimental antiretroviral agents or
        those containing zidovudine or ritonavir, cobicistat or similar potent CYP3 inhibitors are
        prohibited. In order to be eligible, patients taking zidovudine or ritonavir, or cobicistat
        or other CYP3 inhibitors must change to a different regimen 7 days prior to therapy
        initiation. Subjects must be on HAART for at least 12 weeks prior to therapy.
        Note: Patients with pre-existing autoimmune conditions are NOT excluded unless there is an
        autoimmune condition requiring active, ongoing systemic immunosuppressive therapy. However,
        careful consideration should be given to patients with pre-existing autoimmune conditions
        who may need pembrolizumab. Any concerns regarding patients with pre-existing autoimmune
        conditions and eligibility should be reviewed with the study PI.

Study details

Hodgkin Lymphoma

NCT06377566

Memorial Sloan Kettering Cancer Center

1 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.